292 related articles for article (PubMed ID: 19707459)
1. Novel microtubule-targeting agents - the epothilones.
Cheng KL; Bradley T; Budman DR
Biologics; 2008 Dec; 2(4):789-811. PubMed ID: 19707459
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with epothilones in patients with breast cancer.
Buzdar AU
Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S71-8. PubMed ID: 18637402
[TBL] [Abstract][Full Text] [Related]
3. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues.
Fumoleau P; Coudert B; Isambert N; Ferrant E
Ann Oncol; 2007 Jul; 18 Suppl 5():v9-15. PubMed ID: 17656562
[TBL] [Abstract][Full Text] [Related]
4. Epothilones: clinical update and future directions.
Donovan D; Vahdat LT
Oncology (Williston Park); 2008 Apr; 22(4):408-16; discussion 416, 421, 424 passim. PubMed ID: 18472615
[TBL] [Abstract][Full Text] [Related]
5. Epothilones: tubulin polymerization as a novel target for prostate cancer therapy.
Lee JJ; Kelly WK
Nat Clin Pract Oncol; 2009 Feb; 6(2):85-92. PubMed ID: 19048010
[TBL] [Abstract][Full Text] [Related]
6. The epothilones: how pharmacology relates to clinical utility.
Michaud LB
Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389
[TBL] [Abstract][Full Text] [Related]
7. Clinical studies with epothilones for the treatment of metastatic breast cancer.
Vahdat LT
Semin Oncol; 2008 Apr; 35(2 Suppl 2):S22-30; quiz S40. PubMed ID: 18410796
[TBL] [Abstract][Full Text] [Related]
8. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
[TBL] [Abstract][Full Text] [Related]
9. Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review.
Zagouri F; Sergentanis TN; Chrysikos D; Dimopoulos MA; Bamias A
Onco Targets Ther; 2015; 8():2187-98. PubMed ID: 26316786
[TBL] [Abstract][Full Text] [Related]
10. New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilones.
Pronzato P
Drugs; 2008; 68(2):139-46. PubMed ID: 18197722
[TBL] [Abstract][Full Text] [Related]
11. Novel cytotoxic agents: epothilones.
Goodin S
Am J Health Syst Pharm; 2008 May; 65(10 Suppl 3):S10-5. PubMed ID: 18463327
[TBL] [Abstract][Full Text] [Related]
12. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
13. Epothilones in the treatment of cancer.
Larkin JM; Kaye SB
Expert Opin Investig Drugs; 2006 Jun; 15(6):691-702. PubMed ID: 16732719
[TBL] [Abstract][Full Text] [Related]
14. Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting.
Cigler T; Vahdat L
Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S166-70. PubMed ID: 19158037
[TBL] [Abstract][Full Text] [Related]
15. Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
Cortes J; Baselga J
Oncologist; 2007 Mar; 12(3):271-80. PubMed ID: 17405891
[TBL] [Abstract][Full Text] [Related]
16. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
Vahdat L
Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
[TBL] [Abstract][Full Text] [Related]
17. Epothilones in development for non--small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance.
Edelman MJ; Shvartsbeyn M
Clin Lung Cancer; 2012 May; 13(3):171-80. PubMed ID: 22133291
[TBL] [Abstract][Full Text] [Related]
18. Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues.
Fornier MN
Clin Breast Cancer; 2007 Oct; 7(10):757-63. PubMed ID: 18021476
[TBL] [Abstract][Full Text] [Related]
19. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
Rivera E; Lee J; Davies A
Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
[TBL] [Abstract][Full Text] [Related]
20. Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
Egerton N
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1005-12. PubMed ID: 20886213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]